Enclomiphene

The trans-isomer of clomiphene, used off-label to raise natural testosterone by blocking estrogen feedback at the pituitary — the "raise your test without shutting it down" pitch. The standard alternative offered to younger men who balk at lifetime TRT.

Enclomiphene is one of the two isomers that make up clomiphene, separated out. It blocks oestrogen receptors in the hypothalamus and pituitary, which removes the negative-feedback signal that normally tells the brain to slow down. The brain reads that as low oestrogen and increases LH and FSH, which drives the testes to make more of their own testosterone. That is the key difference from testosterone therapy: it raises testosterone by stimulating your own production rather than replacing it, so it does not shut down the axis and does not suppress sperm production the way exogenous testosterone does.

It reliably raises LH, FSH and total testosterone while PRESERVING fertility — several decent trials show this, and that combination is genuinely unique versus TRT. What is less proven: whether the raised number translates into the symptomatic benefits men actually want, where trial results are much softer.

• Phase III trials in 256 men showed it raises testosterone and LH, and preserved sperm CONCENTRATION relative to testosterone gel over 16 weeks. That is not the same as preserving fertility — conception, pregnancy and live birth were never measured, and FDA explicitly concluded semen parameters do not establish fertility. Hormone effects: Moderate. Sperm-concentration preservation: Moderate. Actual fertility: None shown.
• A phase III programme was run and FDA issued a Complete Response Letter — not a paperwork formality, but a finding that the studies did not adequately demonstrate clinically meaningful patient benefit, alongside design and titration deficiencies. Biochemical efficacy was shown; benefit to how men actually feel and function was not. It is not an approved medicine in the US, which is the fact most of its marketing omits.
• Almost everything sold direct-to-consumer online is compounded or grey-market rather than an approved product. Compounding is possible only because enclomiphene sits in FDA's Category 1 of nominated bulk substances — temporary enforcement discretion while evaluation continues, not approval, and not a blanket finding that any given compounded product is lawful.
• Long-term safety data is limited. Most trials ran months, not years, and the consequences of sustained oestrogen-receptor blockade in men over years are not well characterised.
• Clomiphene, the parent mixture, has a longer off-label track record. The popular claim that enclomiphene is cleaner because the other isomer carries the side-effect baggage is NOT established — FDA found zuclomiphene's contribution insufficiently understood, and enclomiphene's own trials reported blurred vision, aggression, and serious events including thromboembolic and cardiovascular ones with uncertain causality.

FDA reports a half-life of roughly ten hours — the "builds up for weeks" claim that circulates is wrong, though hormonal effects can outlast drug levels. It is not a steroid and does not aromatise. Because it works upstream on the axis, it only works if the testes can still respond — it does nothing for primary testicular failure, which is why the underlying cause matters before anything else.

Generally better tolerated than mixed clomiphene (the zuclomiphene isomer carries the mood/visual baggage), but mood changes and rare visual disturbances still occur — any visual symptom means stop. Long-term data is thin. The subtle trap: a higher lab number with unchanged symptoms invites endless dose-chasing.

• Anyone with primary testicular failure, where it cannot work
• Anyone with a history of blood clots
• Anyone with liver disease
• Anyone who develops visual disturbance on it
• Anyone in tested sport
• Anyone treating themselves without ever having established why testosterone is low

• Testosterone therapy, which suppresses the axis this drug works through, making them largely opposed.
• Aromatase inhibitors, frequently stacked with it and pushing oestrogen low enough to harm bone and libido.
• Any drug affecting liver enzyme clearance.
• Tested sport, where it is a prohibited substance as a hormone modulator.

• This is a prescription-style drug needing diagnosis and supervision by a licensed clinician — a lab panel does not make self-use acceptable. What a clinician would follow: the whole hormonal picture (testosterone, LH, FSH, oestradiol), since the mechanism is a feedback change and single numbers mislead.
• Haematocrit, which can rise as testosterone does.
• Vision, specifically. Visual disturbance is a recognised effect of this drug class and is a reason to stop and be assessed rather than to continue.
• Mood, which some users report worsening.
• Lipids and blood pressure.

Because the half-life is long, effects taper over one to two weeks rather than stopping. Testosterone and LH drift back toward wherever they were before — this is not a cure and the underlying cause remains whatever it was. Unlike stopping testosterone therapy there is no suppressed-axis gap to fall into, which is the genuine advantage of working through your own system. Anyone whose testosterone was low for a reason that was never investigated will simply return to that starting point.

US: never FDA-approved as a standalone (the NDA was rejected) — prescribed via compounding pharmacies, a legal but quality-variable channel.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
  Arch Endocrinol Metab, 2025
• Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
  Fertil Steril, 2014
• British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism
  World J Mens Health, 2026

• Safety and efficacy of enclomiphene and clomiphene for hypogonadal menTransl Androl Urol · 2024
• Enclomiphene citrate for the treatment of secondary male hypogonadismExpert Opin Pharmacother · 2016
• Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trialsArch Endocrinol Metab · 2025
• Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in menIDrugs · 2009
• Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadismExpert Rev Endocrinol Metab · 2019
• Clomiphene Citrate and Enclomiphene Hydrochloride Exposure Is Associated With Interfrontal Suture Fusion in ZebrafishPlast Surg (Oakv) · 2023
• Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacementBJU Int · 2016
• Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective StudyCureus · 2023
• Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosteroneFertil Steril · 2014
• Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gelJ Sex Med · 2013
• British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male HypogonadismWorld J Mens Health · 2026
• Enclomiphene does not alter the postpartum interval of suckled beef cowsJ Anim Sci · 1991